194 related articles for article (PubMed ID: 34166980)
1. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
Ling Q; Li F; Zhang X; Mao S; Lin X; Pan J; Ye W; Wei W; Qian Y; Hu C; Huang X; Wang J; Wang H; Huang J; Wang Y; Jin J
EBioMedicine; 2021 Jul; 69():103441. PubMed ID: 34166980
[TBL] [Abstract][Full Text] [Related]
2. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.
Chen J; Mu Q; Li X; Yin X; Yu M; Jin J; Li C; Zhou Y; Zhou J; Suo S; Lu D; Jin J
Oncotarget; 2017 Jun; 8(25):40318-40326. PubMed ID: 28454099
[TBL] [Abstract][Full Text] [Related]
4. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis.
Qiu Y; Bai L; Zhao H; Mei X
BMC Cancer; 2024 Apr; 24(1):520. PubMed ID: 38658865
[TBL] [Abstract][Full Text] [Related]
6. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
[TBL] [Abstract][Full Text] [Related]
8. Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia.
Wei W; Huang S; Ling Q; Mao S; Qian Y; Ye W; Li F; Pan J; Lin X; Huang J; Huang X; Zhai Y; Sun J; Jin J
J Transl Med; 2022 Jul; 20(1):299. PubMed ID: 35794605
[TBL] [Abstract][Full Text] [Related]
9. PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway.
Bai Y; Liu X; Qi X; Liu X; Peng F; Li H; Fu H; Pei S; Chen L; Chi X; Zhang L; Zhu X; Song Y; Wang Y; Meng S; Jiang T; Shao S
EBioMedicine; 2019 Apr; 42():311-325. PubMed ID: 30922965
[TBL] [Abstract][Full Text] [Related]
10. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
11. Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia.
Li F; Ling Q; Lian J; Chen Y; Hu C; Yang M; Zhang X; Li C; Mao S; Ye W; Li X; Lin X; Wei W; Huang X; Pan J; Qian Y; Wang J; Lu Y; Jin J
Cancer Med; 2023 Apr; 12(7):8319-8330. PubMed ID: 36621846
[TBL] [Abstract][Full Text] [Related]
12. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
13. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways.
Shi X; Zhu M; Gong Z; Yang T; Yu R; Wang J; Zhang Y
Food Chem Toxicol; 2020 Feb; 136():110960. PubMed ID: 31726078
[TBL] [Abstract][Full Text] [Related]
14. XPO1 is a new target of homoharringtonine (HHT): Making NPMc
Xue J; Chu P; Gao W; Wang F; Gao Y; Liu S; Kang Z; Yan J; Wang H
Biochem Biophys Res Commun; 2023 Oct; 675():155-161. PubMed ID: 37473530
[TBL] [Abstract][Full Text] [Related]
15. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.
Yuan F; Li D; Li G; Cheng C; Wei X
Ann Transl Med; 2022 Apr; 10(8):490. PubMed ID: 35571387
[TBL] [Abstract][Full Text] [Related]
16. CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy.
Shang J; Chen WM; Liu S; Wang ZH; Wei TN; Chen ZZ; Wu WB
Leuk Res; 2019 Oct; 85():106198. PubMed ID: 31401408
[TBL] [Abstract][Full Text] [Related]
17. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Li X; Li C; Jin J; Wang J; Huang J; Ma Z; Huang X; He X; Zhou Y; Xu Y; Yu M; Huang S; Yan X; Li F; Pan J; Wang Y; Yu Y; Jin J
EBioMedicine; 2018 Dec; 38():47-56. PubMed ID: 30472087
[TBL] [Abstract][Full Text] [Related]
18. Homoharringtonine deregulates
Chen XJ; Zhang WN; Chen B; Xi WD; Lu Y; Huang JY; Wang YY; Long J; Wu SF; Zhang YX; Wang S; Li SX; Yin T; Lu M; Xi XD; Li JM; Wang KK; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2220-2225. PubMed ID: 30659143
[TBL] [Abstract][Full Text] [Related]
19. The role of the novel LincRNA uc002jit.1 in NF-kB-mediated DNA damage repair in acute myeloid leukemia cells.
Li D; Yu Z; Wang T; Li Y; Chen X; Wu L
Exp Cell Res; 2020 Jun; 391(2):111985. PubMed ID: 32259522
[TBL] [Abstract][Full Text] [Related]
20. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]